文献速递结核与非结核分枝杆菌

含氯法齐明与利福喷丁的3个月方案治疗药物敏感性结核:Clo-Fast随机对照2c期试验

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
PubMed 文献 · Lancet Infect Dis · 2025-09-04

Clo-Fast是一项在5国6中心开展的开放标签2c期随机试验,比较含氯法齐明与利福喷丁的3个月方案(加氯法齐明负荷剂量)与标准6个月方案治疗药物敏感性肺结核。因缺乏临床疗效试验提前终止,12周痰培养转阴率两组无统计学差异,但试验组3级及以上不良事件和65周不良复合结局比例显著更高。

要点

  • 3个月含氯法齐明利福喷丁方案12周培养转阴率与标准6个月方案无统计学差异。
  • 试验组3级及以上不良事件发生率为45%,显著高于对照组的16%。
  • 试验组65周不良复合结局累积概率为52%,显著高于对照组的27%。

核心结论

  • 含氯法齐明与利福喷丁的3个月方案12周培养转阴率与标准治疗无统计学差异,但不良复合临床结局及3级及以上不良事件比例不可接受地高。

研究设计与样本

  • Clo-Fast为开放标签2c期随机试验,在5国6中心招募104例药物敏感性肺结核患者,随机分为3组。
  • 组1(n=58)接受8周利福喷丁-异烟肼-吡嗪酰胺-乙胺丁醇-氯法齐明(含2周300 mg氯法齐明负荷剂量)后5周利福喷丁-异烟肼-吡嗪酰胺-氯法齐明,共13周。
  • 组2(n=31)为对照,接受8周异烟肼-利福平-吡嗪酰胺-乙胺丁醇后18周利福平-异烟肼。
  • 组3(n=15)前4周与组1相同但不含氯法齐明负荷剂量(100 mg每日),用于评估负荷剂量对药代动力学的影响。
  • 主要疗效终点为12周时痰培养转阴时间;主要安全性终点为65周内发生任何3级及以上不良事件的比例。

主要发现

  • 试验因缺乏临床疗效提前终止。

关键数值与推荐

  • 入组标准为18岁及以上、痰涂片抗酸杆菌阳性或分子结核检测阳性且对利福平和异烟肼敏感的肺结核患者。
  • HIV感染者CD4+细胞计数≥100 cells per mm3可参与。
  • 随机分组按HIV状态和胸部X线进展性疾病分层。

临床怎么用

  • 该3个月含氯法齐明利福喷丁方案虽培养转阴率与标准治疗相当,但不良事件和不良结局显著增加,不支持临床推广使用。
  • 药物敏感性肺结核目前仍应以标准6个月方案为治疗基础。

局限性

  • 试验因缺乏临床疗效提前终止,样本量有限(共104例)。
  • 为开放标签设计,非盲法评估结局。
  • 组3样本量小(n=15),仅用于药代动力学评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis. METHODS: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries. Participants aged 18 years or older with pulmonary tuberculosis who were sputum smear positive for acid-fast bacilli or molecular tuberculosis assay positive (with Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid) were eligible for enrolment. Individuals with HIV infection with a CD4+ cell count ≥100 cells per mm3 could participate. Participants were randomly assigned in a 2:1 ratio (group 1: group 2) or a 2:1:1 ratio (group 1: group 2: group 3), depending on consent to participate in the intensive pharmacokinetic visits required in group 3, using a central web-based system with permuted blocks. The group 1 regimen included 8 weeks of rifapentine-isoniazid-pyrazinamide-ethambutol-clofazimine, with a 2-week 300 mg clofazimine loading dose, followed by 5 weeks of rifapentine-isoniazid-pyrazinamide-clofazimine (13 weeks total). The group 2 control regimen included 8 weeks of isoniazid-rifampicin-pyrazinamide-ethambutol followed by 18 weeks of rifampicin-isoniazid. Group 3 was identical to group 1 over the first 4 weeks of treatment, except that the regimen was administered without a clofazimine loading dose (100 mg daily); after 4 weeks of group 3 treatment, participants transitioned to local standard of care to complete treatment. Group 3 was designed to assess the effect of a 2-week loading dose on clofazimine pharmacokinetics. Randomisation was stratified by HIV status and advanced disease on chest radiograph. The primary efficacy endpoint was time to sputum culture-negative status by 12 weeks. The primary safety endpoint was the proportion of participants experiencing any grade 3 or worse adverse event over 65 weeks. The key secondary endpoint was unfavourable clinical or bacteriological outcomes by week 65. The efficacy analysis population contained participants assigned to groups 1 and 2 who were not late exclusions (no positive culture at screening, entry, or week 1, or if rifampicin resistance or isoniazid resistance was detected at screening or entry); the safety analysis population contained all randomly assigned participants who took at least one dose of treatment. The trial was registered with ClinicalTrials.gov ID: NCT04311502. FINDINGS: 104 participants were randomly assigned to group 1 (n=58), group 2 (n=31), and group 3 (n=15). 82 (79%) were male and 74 (71%) had radiographically advanced disease; 30 (29%) were people with HIV. The trial was stopped early for lack of clinical efficacy. For the primary efficacy outcome, 49 (89%) of 55 group 1 participants and 28 (90%) of 31 group 2 participants had stable sputum culture conversion by week 12 (adjusted hazard ratio 1·21 [90% CI 0·82-1·79]; p=0·2089). Adverse events grade 3 or worse occurred in 26 (45%) of 58 group 1 participants and five (16%) of 31 group 2 participants (difference 30%, 90% CI 14-45; p=0·002). The cumulative probability of a week 65 unfavourable outcome was 52% (95% CI 37-69) in group 1 versus 27% (14-50) in group 2 (p=0·049). INTERPRETATION: Although the trial was stopped early, we found that a 3-month regimen containing clofazimine and rifapentine had 12-week culture conversion rates that did not differ statistically from the standard of care. The regimen was associated with an unacceptably high proportion of participants with unfavourable composite clinical outcomes and grade 3 or worse adverse events. FUNDING: US National Institutes of Health Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) and the National Institute of Allergy and Infectious Diseases.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Metcalfe JZ, Weir IR, Scarsi KK, et al. A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infect Dis. 2025. PMID: 40915311. doi:10.1016/S1473-3099(25)00436-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。